NVP-1805R2 by NVP Healthcare for Unspecified Cardiovascular Disorders: Likelihood of Approval

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

Researchers discover NFIC molecule that may prevent pancreatic cancer

The pancreas, located behind the stomach, manages the energy supply in our body. It does so by secreting proteins (enzymes) responsible for glucose – the

July 21, 2023

Potential for peptides to replace antibodies in radiopharma, says WuXi AppTec exec – Pharmaceutical Technology

Radiopharmaceuticals have taken off in recent years, with several high-profile deals signed by big pharma. Image credit: Shutterstock / Creative_Bird. Amid the boom in the

October 2, 2024

MHRA approves licence change for Pfizer-BioNTech’s vaccine

Share this article The formulation of the Comirnaty vaccine, approved in September 2023, remains unchanged. Credit: Studio Romantic / Shutterstock.com. The UK Medicines and Healthcare

February 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.